| 7.395 0.125 (1.72%) | 05-06 13:47 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 8.78 | 1-year : | 9.49 |
| Resists | First : | 7.52 | Second : | 8.13 |
| Pivot price | 7.28 |
|||
| Supports | First : | 6.53 | Second : | 5.44 |
| MAs | MA(5) : | 7.53 |
MA(20) : | 7.25  |
| MA(100) : | 7.67 |
MA(250) : | 6.24 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 33.7 |
D(3) : | 51.4 |
| RSI | RSI(14): 49.7 |
|||
| 52-week | High : | 9.31 | Low : | 3.66 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EPRX ] has closed below upper band by 48.3%. Bollinger Bands are 23.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.72 - 7.77 | 7.77 - 7.8 |
| Low: | 6.95 - 7 | 7 - 7.04 |
| Close: | 7.19 - 7.27 | 7.27 - 7.34 |
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Wed, 06 May 2026
In Eupraxia’s top-dose EoE cohort, tissue scores improved >90% - Stock Titan
Tue, 05 May 2026
Why 20 shots matter: Eupraxia links fuller dosing to lower EoE scope scores - Stock Titan
Mon, 04 May 2026
Eupraxia Pharmaceuticals Price Target Maintained With a $11.00/Share by HC Wainwright & Co. - Moomoo
Sat, 02 May 2026
Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer - Sahm
Fri, 01 May 2026
Eupraxia Pharmaceuticals: Tambiah to Succeed Mark Kowalski - Moomoo
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 62 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 14.8 (%) |
| Held by Institutions | 30.9 (%) |
| Shares Short | 2,540 (K) |
| Shares Short P.Month | 2,500 (K) |
| EPS | -1.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -39.7 % |
| Return on Equity (ttm) | -68.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.63 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -29 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -7.1 |
| PEG Ratio | 0 |
| Price to Book value | 7.23 |
| Price to Sales | 0 |
| Price to Cash Flow | -15.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|